Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects - ULDS

Study identifier:MB102-088

ClinicalTrials.gov identifier:NCT01135446

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects

Medical condition

Type 2 Diabetes

Phase

Phase 1

Healthy volunteers

Yes

Study drug

dapagliflozin

Sex

All

Actual Enrollment

35

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 May 2010
Primary Completion Date: 01 Jun 2010
Study Completion Date: 01 Jun 2010

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Other

Verification:

Verified 01 Oct 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Bristol-Myers Squibb

Inclusion and exclusion criteria